The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer

The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer. The main questions it aims to answer are: * prognostic value of baseline MRD; * the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before adjuvant chemotherapy initiation and at the first imaging assessment after chemotherapy.

Trial Details

NCT ID
NCT05802407
Phase
NA
Sponsor
Peking Union Medical College Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Later-line therapy
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • patients with pancreatic cancer who had undergone curative-intent surgery (R0 or R1 resection);
  • both sexes, age ≥18 years old;
  • ECOG performance status score ≤2;
  • the expected survival time was ≥3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →